Alnylam Pharmace. buy Chardan Capital
Summary
This prediction ended on 12.10.25 with a price of €396.10. With a performance of 52.23% the BUY prediction by Chardan_Capital was a big success. Chardan_Capital has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Chardan_Capital has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -9.609% | -9.609% | 29.174% |
| iShares Core DAX® | 0.191% | 4.771% | 20.559% |
| iShares Nasdaq 100 | -0.614% | 3.137% | 5.816% |
| iShares Nikkei 225® | 0.599% | 8.016% | 21.913% |
| iShares S&P 500 | -0.036% | 3.593% | 3.588% |
Comments by Chardan_Capital for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Current prediction by Chardan_Capital for Alnylam Pharmace.
Stopped prediction by Chardan_Capital for Alnylam Pharmace.
Alnylam Pharmace.
16.02.24
16.02.25
17.02.25
Alnylam Pharmace.
08.08.23
08.08.24
09.08.24

